Advanced Biomed (ADVB) Cash from Financing Activities (2024 - 2026)

Advanced Biomed has disclosed Cash from Financing Activities across 3 years of filings, most recently posting -$373480.0 for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at -$373480.0, down 106.0% year-over-year; the trailing twelve-month figure through Mar 2026 was -$376007.0 (down 105.35% YoY), and the FY2025 annual result was $5.9 million, up 217.88% from the prior year.
• Cash from Financing Activities came in at -$373480.0 for Q1 2026 at Advanced Biomed, down from $315477.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $6.2 million in Q1 2025 to a low of -$765466.0 in Q2 2025.
• The 3-year median for Cash from Financing Activities is $323536.0 (2024), against an average of $801055.0.
• Peak annual rise in Cash from Financing Activities reached 1007.96% in 2025, while the deepest fall reached 336.59% in 2025.
• Advanced Biomed's Cash from Financing Activities stood at $78327.0 in 2024, then surged by 302.77% to $315477.0 in 2025, then tumbled by 218.39% to -$373480.0 in 2026.
• The last three Cash from Financing Activities figures came in at -$373480.0 (Q1 2026), $315477.0 (Q4 2025), and $447462.0 (Q3 2025), per Business Quant data.